Results of the PANOVA-3 open-label, randomized phase 3 study show that compared with chemotherapy alone, the concomitant use of adding…
pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
Now published in EJC – European Journal of Cancer (1), results of a retrospective study led by investigators of VHIO’s…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with…
